GS
IOVA icon

GTS Securities’s Iovance Biotherapeutics IOVA Stock Holding History

GTS Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,800
Closed -$131K – 4207
2023
Q3 		$131K Buy
+28,800
New +$188K ﹤0.01% 3547

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GTS Securities's IOVA Position: Q2 2026 in Review

GTS Securities increased its Iovance Biotherapeutics (IOVA) stake by 45% in Q2 2026, buying an estimated $16.9K and bringing the position to 14,461 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1272.

GTS Securities first reported a position in IOVA in Q2 2023 and has held it in 6 quarters since. The position peaked at $542K in Q4 2023. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • GTS Securities held 14,461 shares of Iovance Biotherapeutics worth $60.2K as of Q2 2026.
  • GTS Securities bought 4,457 Iovance Biotherapeutics shares in Q2 2026, an estimated $16.9K.
  • Iovance Biotherapeutics made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1272 holding.
  • GTS Securities first reported a position in Iovance Biotherapeutics in Q2 2023 and has held it in 6 quarters since.
  • GTS Securities's Iovance Biotherapeutics position peaked at $542K in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.